Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥5,911 JPY
Change Today +75.00 / 1.29%
Volume 2.6M
As of 2:00 AM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

takeda pharmaceutical co ltd (4502) Snapshot

Open
¥5,833
Previous Close
¥5,836
Day High
¥5,948
Day Low
¥5,825
52 Week High
03/6/15 - ¥6,657
52 Week Low
10/17/14 - ¥4,338
Market Cap
4.7T
Average Volume 10 Days
2.2M
EPS TTM
¥-185.58
Shares Outstanding
790.0M
EX-Date
09/28/15
P/E TM
--
Dividend
¥180.00
Dividend Yield
3.05%
Current Stock Chart for TAKEDA PHARMACEUTICAL CO LTD (4502)

Related News

No related news articles were found.

takeda pharmaceutical co ltd (4502) Details

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, sale, and import/export of pharmaceutical drugs worldwide. It provides products in various therapeutic areas, including cardiovascular and metabolic, respiratory and immunology, oncology, central nervous system, general medicine, vaccines, and consumer healthcare drugs and quasi-drugs. The company has strategic partnership with BioMotiv, LLC; and a collaboration agreement with Mersana Therapeutics Inc. and Queen Mary University of London. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan.

Founded in 1781

takeda pharmaceutical co ltd (4502) Top Compensated Officers

Chief Medical & Scientific Officer, Director ...
Total Annual Compensation: ¥332.0M
Managing Director of Special Missions and Dir...
Total Annual Compensation: ¥93.0M
Compensation as of Fiscal Year 2014.

takeda pharmaceutical co ltd (4502) Key Developments

Takeda Announces the Resignation of CFO François-Xavier Roger

Takeda Pharmaceutical Company Limited announced that François-Xavier Roger has resigned effective June 26, 2015 to become chief financial officer of Nestlé S.A.

Takeda Pharmaceutical Company Limited Presents at BIO International Convention 2015, Jun-17-2015 10:15 AM

Takeda Pharmaceutical Company Limited Presents at BIO International Convention 2015, Jun-17-2015 10:15 AM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States.

Takeda Pharmaceutical Company Limited Presents Additional Data from Alogliptin's Examine Cardiovascular Safety Outcomes Trial at American Diabetes Association's 75th Scientific Sessions

Takeda Pharmaceutical Company Limited announced additional post-hoc analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) outcomes trial (CVOT), which assessed patients with Type 2 diabetes who were at a high CV risk due to recent acute coronary syndrome (ACS). During an oral presentation at the American Diabetes Association's 75th Scientific Sessions in Boston, Massachusetts, data from EXAMINE indicated that composite rates of major adverse cardiac events (MACE) were similar for alogliptin compared with placebo in patients taking angiotensin-converting enzyme (ACE) inhibitors [11.4% vs. 11.8%, HR = 0.97, 95% CI, 0.79 – 1.19, p=0.76]. The data also suggested that there were no significant differences for rates of CV death or hospitalized heart failure (HHF) on alogliptin compared to placebo in ACE inhibitor treated patients. Additional post-hoc analyses presented from the EXAMINE data showed that alogliptin compared with placebo did not significantly increase the incidence of cardiac ischemic events [24.6 vs. 25.1, HR=0.98, 95% CI, 0.87 – 1.10, p=0.72] and cardiovascular hospitalizations [16.4 vs. 16.0, HR=1.02, 95% CI, 0.89 – 1.17, p=0.73]. A post-hoc analysis evaluated adjudicated CV events in EXAMINE, a trial of patients with Type 2 diabetes and recent ACS, according to ACE inhibitor use. Risks of CV death, nonfatal myocardial infarction (MI) and stroke, and CV death or HHF were analyzed. Approximately 62% of patients enrolled in the EXAMINE trial were using an ACE inhibitor (1,681 on alogliptin; 1,642 on placebo). The post-hoc analysis showed that CV outcomes were not different for alogliptin compared with placebo in high CV risk patients with Type 2 diabetes on ACE inhibitors. Additional post-hoc analyses of the data also examined all cardiac ischemic events and CV hospitalizations in the trial. Researchers from the EXAMINE Steering Committee calculated the incident rates of cardiac ischemic outcomes (CV death, MI, stroke, unstable angina and revascularization) and CV hospitalizations. There were no significant differences between alogliptin and placebo in the event rates of any of the cardiac ischemic endpoints. Alogliptin is the first dipeptidyl peptidase-4 inhibitor (DPP-4i) to report results on CV safety outcomes in Type 2 diabetes patients who are at a high CV risk due to recent ACS. Data from the EXAMINE trial has been submitted to several regulatory bodies for their review. Alogliptin has been studied as a monotherapy and in combination with metformin, a sulfonylurea (SU), a thiazolidinedione (TZD), and insulin in a comprehensive global clinical program comprising of more than 50 clinical studies involving approximately 1,000 healthy adult patients and more than 17,000 adult patients with Type 2 diabetes.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4502:JP ¥5,911.00 JPY +75.00

4502 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $49.52 USD +0.51
Baxter International Inc $71.05 USD +0.40
Becton Dickinson and Co $142.72 USD +0.94
Incyte Corp $102.49 USD +1.67
Merck KGaA €90.01 EUR +0.21
View Industry Companies
 

Industry Analysis

4502

Industry Average

Valuation 4502 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.5x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAKEDA PHARMACEUTICAL CO LTD, please visit www.takeda.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.